Another example is using epidermal growth factor receptor (EGFR) inhibitors successfully to treat lung cancers that harbor mutant EGFR, also using BRAF inhibitors to treat the melanomas carrying mutated BRAF (8–11). This evidence concerns the gene EGFR and lung carcinoma.